The elasticity of drugs demand in Colombia’s pharmaceutical market

Main Article Content

Johanna Vásquez Velásquez
Karoll Gómez Portilla
Elkin Castaño Vélez
José Vicente Cadavid Herrera
Andrés Ramírez Hassan


Elasticity, Pharmaceutics market, AIDS model, Cointegration


Based on a dynamic specification of the AIDS model arisen from cointegration techniques, this research estimated the elasticity of the intra-molecular, brand and generic demand for three tracer conditions: essential hypertension, diabetes and hyperlipidemia both in the non-profit and private Colombian market. The estimate of the intra-molecular demand elasticity allows us to conclude that both brand-name and generic drugs are inelastic to price changes, they are luxury goods according to expenditure elasticity and intra-molecular replacement seems to exist due to the elasticity of substitution.


Download data is not yet available.
Abstract 1263 | PDF (Español) Downloads 581 HTML (Español) Downloads 17880


Akbulutgiller, K. (2008). Application of Almost Ideal Demand System for a Pharmaceu¬tical. Recuperado de: 9ba0-e966521263dd/df15f24f-9815-493d-8bb8-b4166b3fa391.pdf

Alexander, D. L.; Flynn, J. E. & Linkins, L. A. (1994, agosto). Estimates of the demand for ethical pharmaceutical drugs across countries and time. Applied Economics, 26(8), 821-826.

Anderson, G. J. & Blundell, R. W. (1982). Estimation and hypothesis testing in dynamic singular equation systems. Econométrica, 50, 1559-1571.

Anderson, G. J. & Blundell, R. W. (1983). Testing restrictions in a flexible demand system: An application to consum¬ers´ expenditure in Canada”. Review of Economic Studies, 50, 397-410.

Archila, E. J. et al. (2005, junio). Estudio sobre la propiedad intelectual en el sector far¬macéutico colombiano. Informe de Investigación. Fedesarrollo y Fundación Santa Fe de Bogotá. Recuperado de: dc01-2005.PDF

Attfield, C. L. (1997, enero). Estimating a Cointegrating Demand System. European Eco¬nomic Review, 41(1), 61-73.

Caves, R. E. & Williamson, P. J. (1985, diciembre). ¿What is Products Differentiation, Re¬ally? The Journal of Industrial Economics, 34(2), 113-132.

Caves, R. E. & Whinston, M. D. (1991). Patent Expiration, Entry and Competition in the U.S. Pharmaceutical Industry. Brooking Papers on Economics Activity. Microeconomics, 1-66.

Chaudhuri, S.; Golberg, P. K. & Jia, P. (2003, diciembre). Estimating the Effects of Global Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India. National Bureau of Economic Research, Working paper, 10159.

Crawford, G. & Shum, M. (2005, julio). Uncertainty and Learning in Pharmaceutical De¬mand. Econometrica, 73(4), 1137-1173.

Deaton, A. S. & Muellbauer, J. (1980, junio). An Almost Ideal Demand System. American Economic Review, 70(3), 312-326.

Ellison, S. F. et al. (1997, agosto). Characteristics of Demand for Pharmaceutical Pro¬ducts: An Examination of Four Cephalosporin’s. The RAND Journal of Economics, 28(3), 426-446.

Engle, R. F. & Granger, C. (1987, marzo). Cointegration and Error-Correction: Representa¬tion, Estimation, and Testing. Econometrica, 55, pp. 251-276.

Grabowski, H. G. & Vernon, J. M. (1987, agosto). Pioneers, imitators and generics-a simu¬lation model of Schumpeterian competition. The Quarterly Journal of Economics, 102(3), 491-526.

Green, R. & Alston, J. M. (1990, mayo). Elasticities in AIDS Models. American Journal of Agriculture Economic, 72(2), 442-445.

Hellerstein, J. K. (1994, verano). The Importance the Physicians in the Generic versus Trade-name Prescription Decision. The RAND Journal of Economics, 29(1), 108-136.

Jaramillo, H.; Restrepo, J. M. & Latorre, C. (2003, agosto). Mercado de medicamentos, regulación y políticas públicas. Borradores de Investigación. Serie Documentos en Economía, 004328. Recuperado de: investiga¬cion/bi/bi38.pdf

Koukouritakis, M. (2003). Eu Accession Effects on Imports of Manufactures: the Case of Greece. Department of Economics, University of Cyprus. Discussion paper, 02. Recuperado de:

Mejía, R. S. et al. (2002, julio-agosto). La política farmacéutica nacional en Colombia y la reforma de la seguridad social: acceso y uso racional de medicamentos. Cad. Saúde Pública, 18(4), 1025-1039.

Merino, A. (2003). Demand for Pharmaceutical Drugs: a Choice Modelling Experiment. (Tesis Ph.D). Departamento de Economía y Empresa, Universidad Pompeu Fabra. Recuperado de:

Mortimer, O. R. (1998, noviembre). Demand for Prescription Drugs: The Effects of Mana¬ged Care Pharmacy Benefits. Abstr Book Assoc Health Serv Res Meet, 15, 113-114.

Pashardes, P. (1993, julio). Bias in estimating the almost ideal demand system with the Stone index approximation. The Economic Journal, 103(419), 908-915.

Santerre, R. E., Stephen, P. (2000). The pharmaceutical industry. Health Economics: Theo¬ries, Insights, and Industry Studies. The Dryden Press, 508-553.

Stern, S. (1996, diciembre). Market Definition and the Returns to Innovation: Substitu¬tion Patterns in Pharmaceutical Markets. MIT Sloan School & NBER, working paper, 36-46. Recuperado de: NEW researchpage/Publications/Stern%20RX%20Demand.pdf

Zuleta, L. A. & Junca, J. C. (2001, abril). Efectos económicos y sociales de la regulación sobre la industria farmacéutica colombiana: el caso de los estudios de bioequiva¬lencia y biodisponibilidad, de los secretos empresariales y las buenas prácticas de manufactura. Fedesarrollo-Misión Social. Recuperado de: http://www.misionsalud. org/mision/estudio2.pdf

Zuleta, L. A.; Parra, M. L. (1999, julio). Incidencia del régimen de patentes de la industria farmacéutica sobre la economía colombiana. Informe Final. Fedesarrollo. Recupe¬rado de: